Key facts
- ProNovo’s last known valuation is $29.0M (Apr 2025).
- It has raised $13.5M; the latest was Seed Round ($13.5M) in Apr 2025.
- Notable investors include K2VC, 3E Bioventures Capital, Gaorong Ventures, JLS Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for ProNovo
- ·The full record, as it builds
Funding rounds
No funding rounds for ProNovo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProNovo
Developer of targeted pharmaceutical treatments designed for addressing neuropsychiatric conditions. The company's platform utilizes scientific research and technology to create precision therapeutics, enabling healthcare providers to access novel options for the treatment of disorders such as major depressive disorder and schizophrenia, with a focus on addressing clinical needs.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Website
- pronovotx.com/
- Ownership
- Privately Held (backing)
ProNovo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProNovo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProNovo in its N-PORT filings yet. We sweep new filings monthly.